Local standard of care

DRUG7 trials

Conditions

Acute Lung InjuryCOVID-19Chronic Kidney DiseaseHyperkalaemiaMeningioma, MalignantRecurrent High Grade MeningiomaRecurrent Meningioma

Phase 2

Trabectedin for Recurrent Grade II/III Meningioma

CompletedNCT02234050

European Organisation for Research and Treatment of Cancer - EORTCRecurrent High Grade Meningioma

Start: 2015-07-31End: 2019-01-16Updated: 2025-07-10

Regorafenib for Recurrent Meningioma (MIRAGE Trial)

RecruitingNCT06275919

Istituto Oncologico Veneto IRCCSMeningioma, Malignant

Start: 2024-09-23End: 2027-03-01Target: 104Updated: 2026-03-27

177Lu-DOTATATE for Recurrent Meningioma

RecruitingNCT06326190

European Organisation for Research and Treatment of Cancer - EORTCRecurrent Meningioma

Start: 2025-03-10End: 2028-12-22Target: 136Updated: 2025-09-16

Phase 3

The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.

CompletedNCT04328480

Estudios Clínicos Latino AméricaCOVID-19

Start: 2020-04-17End: 2021-04-26Updated: 2021-04-27

Phase 4

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

CompletedNCT05347693

AstraZenecaChronic Kidney Disease, Hyperkalaemia

Start: 2022-03-24End: 2024-12-10Updated: 2025-11-28

Unknown Phase

Study of Renin-angiotensin System in Mechanically Ventilated Subjects

TerminatedNCT03212690

GlaxoSmithKlineAcute Lung Injury

Start: 2018-06-11End: 2019-07-08Updated: 2020-04-01

PERUCONPLASMA: EVALUATING THE USE OF CONVALESCENT PLASMA AS MANAGEMENT OF COVID-19

Active, not recruitingPER-016-20

UNIVERSIDAD PERUANA CAYETANO HEREDIA,

Start: 2020-06-01Target: 98Updated: 2023-11-13

2026-01-021 citations

[177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial

Universität Zürich, ZORA2026-01-01

TIP-05. Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: the MIRAGE trial

Neuro-Oncology2025-11-01

TIP-01. [177Lu]Lu-DOTATATE for recurrent meningioma (LUMEN-1, EORTC-2334-BTG): study protocol for a randomized phase II trial

Neuro-Oncology2025-11-01

P13.14.A REGORAFENIB VERSUS LOCAL STANDARD OF CARE IN PATIENTS WITH GRADE 2-3 MENINGIOMA NO LONGER ELIGIBLE FOR LOCO-REGIONAL TREATMENTS: THE MIRAGE TRIAL

Neuro-Oncology2025-10-01

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

2025-08-04

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: The MIRAGE trial.

Journal of Clinical Oncology2025-05-28

3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.

Journal of Clinical Oncology2023-06-012 citations

Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease

Clinical Kidney Journal2023-03-232 citations

FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities

Clinical Drug Investigation2022-09-293 citations

Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19

JAMA Network Open2021-12-2935 citations

Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.

2021-05-173 citations

Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).

Journal of Clinical Oncology2019-05-2019 citations